Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from BriaCell Therapeutics ( (TSE:BCT) ).
BriaCell Therapeutics reported that 48.31% of its outstanding common shares were represented at its annual general and special meeting for the year ended July 31, 2025, held on March 5, 2026. Shareholders overwhelmingly approved all resolutions, including the re-appointment of MNP LLP as auditors and the election of the full slate of six directors, each receiving more than 97% of votes cast.
The strong support for the board and auditor re-appointment signals shareholder confidence in BriaCell’s current leadership and strategic direction in cancer immunotherapy. The voting outcome reinforces the company’s governance stability as it advances its clinical-stage programs, providing continuity for stakeholders tracking its progress in the competitive biotech sector.
The most recent analyst rating on (TSE:BCT) stock is a Sell with a C$5.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn with likely ongoing financing needs). Technicals are mixed with some shorter-term strength but negative MACD and a price still far below the 200-day average. Valuation contributes limited support due to a negative P/E and no dividend yield.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies designed to transform cancer care. The company targets oncology indications with immune-based treatments, positioning itself within the growing field of cancer immunotherapy for patients with unmet medical needs.
Average Trading Volume: 27,761
Technical Sentiment Signal: Sell
Current Market Cap: C$39.88M
Find detailed analytics on BCT stock on TipRanks’ Stock Analysis page.